The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
The global Circulating Tumor Cell market was valued at US$ 670.2 million in 2023 and is anticipated to reach US$ 1140.7 million by 2030, witnessing a CAGR of 7.9% during the forecast period 2024-2030.
Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cell, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cell.
Report Scope
The Circulating Tumor Cell market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Circulating Tumor Cell market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor Cell companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Menarini-Silicon Biosystems
- Qiagen（Adnagen）
- Clearbridge Biomedics
- Celsee
- Fluidigm
- ApoCell
- Greiner Bio-one
- Advanced Cell Diagnostics
- Aviva Biosciences
- Fluxion Biosciences
- Sysmex
- Epic Sciences
- Cynvenio
- CytoTrack
- Ikonisys
- Vortex BioSciences
- Gilupi
- Biocept
- ScreenCell
- ANGLE
Segment by Type
- CTC Enrichment
- CTC Detection
- CTC Analysis
Segment by Application
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Others
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cell companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumor Cell Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CTC Enrichment
1.2.3 CTC Detection
1.2.4 CTC Analysis
1.3 Market by Application
1.3.1 Global Circulating Tumor Cell Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Breast Cancer
1.3.3 Prostate Cancer
1.3.4 Colorectal Cancer
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cell Market Perspective (2019-2030)
2.2 Circulating Tumor Cell Growth Trends by Region
2.2.1 Global Circulating Tumor Cell Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Circulating Tumor Cell Historic Market Size by Region (2019-2024)
2.2.3 Circulating Tumor Cell Forecasted Market Size by Region (2025-2030)
2.3 Circulating Tumor Cell Market Dynamics
2.3.1 Circulating Tumor Cell Industry Trends
2.3.2 Circulating Tumor Cell Market Drivers
2.3.3 Circulating Tumor Cell Market Challenges
2.3.4 Circulating Tumor Cell Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor Cell Players by Revenue
3.1.1 Global Top Circulating Tumor Cell Players by Revenue (2019-2024)
3.1.2 Global Circulating Tumor Cell Revenue Market Share by Players (2019-2024)
3.2 Global Circulating Tumor Cell Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Circulating Tumor Cell Revenue
3.4 Global Circulating Tumor Cell Market Concentration Ratio
3.4.1 Global Circulating Tumor Cell Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cell Revenue in 2023
3.5 Circulating Tumor Cell Key Players Head office and Area Served
3.6 Key Players Circulating Tumor Cell Product Solution and Service
3.7 Date of Enter into Circulating Tumor Cell Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor Cell Breakdown Data by Type
4.1 Global Circulating Tumor Cell Historic Market Size by Type (2019-2024)
4.2 Global Circulating Tumor Cell Forecasted Market Size by Type (2025-2030)
5 Circulating Tumor Cell Breakdown Data by Application
5.1 Global Circulating Tumor Cell Historic Market Size by Application (2019-2024)
5.2 Global Circulating Tumor Cell Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Circulating Tumor Cell Market Size (2019-2030)
6.2 North America Circulating Tumor Cell Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Circulating Tumor Cell Market Size by Country (2019-2024)
6.4 North America Circulating Tumor Cell Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumor Cell Market Size (2019-2030)
7.2 Europe Circulating Tumor Cell Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Circulating Tumor Cell Market Size by Country (2019-2024)
7.4 Europe Circulating Tumor Cell Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cell Market Size (2019-2030)
8.2 Asia-Pacific Circulating Tumor Cell Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Circulating Tumor Cell Market Size by Region (2019-2024)
8.4 Asia-Pacific Circulating Tumor Cell Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumor Cell Market Size (2019-2030)
9.2 Latin America Circulating Tumor Cell Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Circulating Tumor Cell Market Size by Country (2019-2024)
9.4 Latin America Circulating Tumor Cell Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cell Market Size (2019-2030)
10.2 Middle East & Africa Circulating Tumor Cell Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Circulating Tumor Cell Market Size by Country (2019-2024)
10.4 Middle East & Africa Circulating Tumor Cell Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Menarini-Silicon Biosystems
11.1.1 Menarini-Silicon Biosystems Company Detail
11.1.2 Menarini-Silicon Biosystems Business Overview
11.1.3 Menarini-Silicon Biosystems Circulating Tumor Cell Introduction
11.1.4 Menarini-Silicon Biosystems Revenue in Circulating Tumor Cell Business (2019-2024)
11.1.5 Menarini-Silicon Biosystems Recent Development
11.2 Qiagen（Adnagen）
11.2.1 Qiagen（Adnagen） Company Detail
11.2.2 Qiagen（Adnagen） Business Overview
11.2.3 Qiagen（Adnagen） Circulating Tumor Cell Introduction
11.2.4 Qiagen（Adnagen） Revenue in Circulating Tumor Cell Business (2019-2024)
11.2.5 Qiagen（Adnagen） Recent Development
11.3 Clearbridge Biomedics
11.3.1 Clearbridge Biomedics Company Detail
11.3.2 Clearbridge Biomedics Business Overview
11.3.3 Clearbridge Biomedics Circulating Tumor Cell Introduction
11.3.4 Clearbridge Biomedics Revenue in Circulating Tumor Cell Business (2019-2024)
11.3.5 Clearbridge Biomedics Recent Development
11.4 Celsee
11.4.1 Celsee Company Detail
11.4.2 Celsee Business Overview
11.4.3 Celsee Circulating Tumor Cell Introduction
11.4.4 Celsee Revenue in Circulating Tumor Cell Business (2019-2024)
11.4.5 Celsee Recent Development
11.5 Fluidigm
11.5.1 Fluidigm Company Detail
11.5.2 Fluidigm Business Overview
11.5.3 Fluidigm Circulating Tumor Cell Introduction
11.5.4 Fluidigm Revenue in Circulating Tumor Cell Business (2019-2024)
11.5.5 Fluidigm Recent Development
11.6 ApoCell
11.6.1 ApoCell Company Detail
11.6.2 ApoCell Business Overview
11.6.3 ApoCell Circulating Tumor Cell Introduction
11.6.4 ApoCell Revenue in Circulating Tumor Cell Business (2019-2024)
11.6.5 ApoCell Recent Development
11.7 Greiner Bio-one
11.7.1 Greiner Bio-one Company Detail
11.7.2 Greiner Bio-one Business Overview
11.7.3 Greiner Bio-one Circulating Tumor Cell Introduction
11.7.4 Greiner Bio-one Revenue in Circulating Tumor Cell Business (2019-2024)
11.7.5 Greiner Bio-one Recent Development
11.8 Advanced Cell Diagnostics
11.8.1 Advanced Cell Diagnostics Company Detail
11.8.2 Advanced Cell Diagnostics Business Overview
11.8.3 Advanced Cell Diagnostics Circulating Tumor Cell Introduction
11.8.4 Advanced Cell Diagnostics Revenue in Circulating Tumor Cell Business (2019-2024)
11.8.5 Advanced Cell Diagnostics Recent Development
11.9 Aviva Biosciences
11.9.1 Aviva Biosciences Company Detail
11.9.2 Aviva Biosciences Business Overview
11.9.3 Aviva Biosciences Circulating Tumor Cell Introduction
11.9.4 Aviva Biosciences Revenue in Circulating Tumor Cell Business (2019-2024)
11.9.5 Aviva Biosciences Recent Development
11.10 Fluxion Biosciences
11.10.1 Fluxion Biosciences Company Detail
11.10.2 Fluxion Biosciences Business Overview
11.10.3 Fluxion Biosciences Circulating Tumor Cell Introduction
11.10.4 Fluxion Biosciences Revenue in Circulating Tumor Cell Business (2019-2024)
11.10.5 Fluxion Biosciences Recent Development
11.11 Sysmex
11.11.1 Sysmex Company Detail
11.11.2 Sysmex Business Overview
11.11.3 Sysmex Circulating Tumor Cell Introduction
11.11.4 Sysmex Revenue in Circulating Tumor Cell Business (2019-2024)
11.11.5 Sysmex Recent Development
11.12 Epic Sciences
11.12.1 Epic Sciences Company Detail
11.12.2 Epic Sciences Business Overview
11.12.3 Epic Sciences Circulating Tumor Cell Introduction
11.12.4 Epic Sciences Revenue in Circulating Tumor Cell Business (2019-2024)
11.12.5 Epic Sciences Recent Development
11.13 Cynvenio
11.13.1 Cynvenio Company Detail
11.13.2 Cynvenio Business Overview
11.13.3 Cynvenio Circulating Tumor Cell Introduction
11.13.4 Cynvenio Revenue in Circulating Tumor Cell Business (2019-2024)
11.13.5 Cynvenio Recent Development
11.14 CytoTrack
11.14.1 CytoTrack Company Detail
11.14.2 CytoTrack Business Overview
11.14.3 CytoTrack Circulating Tumor Cell Introduction
11.14.4 CytoTrack Revenue in Circulating Tumor Cell Business (2019-2024)
11.14.5 CytoTrack Recent Development
11.15 Ikonisys
11.15.1 Ikonisys Company Detail
11.15.2 Ikonisys Business Overview
11.15.3 Ikonisys Circulating Tumor Cell Introduction
11.15.4 Ikonisys Revenue in Circulating Tumor Cell Business (2019-2024)
11.15.5 Ikonisys Recent Development
11.16 Vortex BioSciences
11.16.1 Vortex BioSciences Company Detail
11.16.2 Vortex BioSciences Business Overview
11.16.3 Vortex BioSciences Circulating Tumor Cell Introduction
11.16.4 Vortex BioSciences Revenue in Circulating Tumor Cell Business (2019-2024)
11.16.5 Vortex BioSciences Recent Development
11.17 Gilupi
11.17.1 Gilupi Company Detail
11.17.2 Gilupi Business Overview
11.17.3 Gilupi Circulating Tumor Cell Introduction
11.17.4 Gilupi Revenue in Circulating Tumor Cell Business (2019-2024)
11.17.5 Gilupi Recent Development
11.18 Biocept
11.18.1 Biocept Company Detail
11.18.2 Biocept Business Overview
11.18.3 Biocept Circulating Tumor Cell Introduction
11.18.4 Biocept Revenue in Circulating Tumor Cell Business (2019-2024)
11.18.5 Biocept Recent Development
11.19 ScreenCell
11.19.1 ScreenCell Company Detail
11.19.2 ScreenCell Business Overview
11.19.3 ScreenCell Circulating Tumor Cell Introduction
11.19.4 ScreenCell Revenue in Circulating Tumor Cell Business (2019-2024)
11.19.5 ScreenCell Recent Development
11.20 ANGLE
11.20.1 ANGLE Company Detail
11.20.2 ANGLE Business Overview
11.20.3 ANGLE Circulating Tumor Cell Introduction
11.20.4 ANGLE Revenue in Circulating Tumor Cell Business (2019-2024)
11.20.5 ANGLE Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
